Target Malaria's gene-engineering programme held Burkinabé approvals from the ANB, ANEVE, the national ethics committee and the host villages. Burkina Faso suspended it in August 2025. The episode shows the gap between a biosafety permit and public acceptance.
On 11 August 2025, researchers from Target Malaria carried out a small-scale release of male-biased genetically modified mosquitoes in Burkina Faso (Target Malaria). The insects were engineered to produce almost exclusively male offspring. Seven days later, on 18 August, judicial police arrived at the Research Institute in Health Sciences in Bobo-Dioulasso. Target Malaria had used the institute as its institutional home in the country since 2012; police sealed the facility. Four days after that, on 22 August, the Ministry of Higher Education, Research and Innovation terminated all Target Malaria activities on Burkinabé soil, indefinitely.
Thirteen years of partnership ended eleven days after the open-field release. The episode raises a governance question that reaches well beyond Burkina Faso: what turns a fully permitted research programme into one a government stops?
What was released
The 11 August release was not a gene drive. It was a strain of Anopheles gambiae engineered with a "male bias" trait, a Y-chromosome modification that skews offspring towards male. The goal is to suppress local mosquito populations, because only females bite and only females transmit malaria. The strain does not contain a self-propagating drive mechanism. Target Malaria's own statement, citing its regulatory file, describes the release as "non-gene drive genetically modified male bias mosquitoes". It says the release took place "in accord with the terms and conditions of the ANB and ANEVE permits."
Those acronyms matter. Burkina Faso's National Biosafety Agency (ANB) and National Environmental Assessment Agency (ANEVE) had both issued authorisations in July 2025. The country's Ethics Committee for Health Research had cleared the protocol, and the host villages had given recorded community consent. Target Malaria had also run a 2019 release of sterile males in the village of Bana, the first such release in Africa, under the same regulatory regime. The 2025 work was designed as the second formal step in a phased programme.
Every regulatory approval had been granted. The approvals did not prevent the suspension.
What happened to the mosquitoes and the science
After the suspension order, the government ordered the destruction of the transgenic strains held in the institute's insectary. Samples were disposed of, and the Bobo-Dioulasso facility, built up over more than a decade, was sealed.
The loss of the insectary lines is the harder one to recover from. Mosquito strains carrying carefully validated transgenes represent years of work, and they are not stored in central global biobanks the way mammalian cell lines are. A small-scale village release was meant to support two things. The first was validation of the male-bias suppression effect under West African field conditions. The second was a regulatory dossier other African countries could build on. Both ended on 22 August.
The effect in Uganda
The effect extended beyond Burkina Faso. Target Malaria is a multi-country consortium with active programmes in Ghana and Uganda. The Ugandan team, led by principal investigator Jonathan Kayondo, had been planning its own first releases on a timeline anchored to the Burkinabé data. Kayondo, quoted in Nature's reporting, said scientists "had not anticipated the decision."
The cost to Uganda takes several forms: disrupted timelines, reshaped field-study plans, higher costs because each country must now begin validation from a colder start, and the loss of the regulatory precedent a phased Burkinabé programme would have set across the African Union. Ghana's situation is comparable. Mali's programme has its own security constraints, which limit how far any single country's experience transfers.
The NCSU Genetic Engineering and Society Center, in its September 2025 post-mortem, framed the wider implication plainly. The centre called the Burkinabé suspension a "cautionary tale for Ghana and Uganda" that may lead to "heightened scrutiny and delays for similar projects" across the continent. It also noted that "sovereignty narratives remain deeply influential" in shaping which biotechnologies African publics accept.
Why a permitted project was suspended
The question is why a fully permitted project was suspended so quickly. The technical regulators (ANB, ANEVE, the Ethics Committee) were performing one task, while the political environment was changing on a different track.
Civil society organisations, COPAGEN, Terre à Vie, COASP and CVAB, had organised against the project. The NCSU centre reports that they raised ecological concerns about genetic stability, mosquito adaptation and removing mosquito populations entirely. They framed the debate in political and ethical terms. They warned about the influence of major donors, particularly the Gates Foundation, and about the marginalisation of locally defined solutions. The NCSU centre links the reception of those arguments to a broader policy shift toward sovereignty and independence from external influence, after which the government became increasingly cautious.
The centre's bluntest observation concerned Target Malaria's own social-engagement work. It functioned, structurally, as "a feedback mechanism rather than a driver capable of reshaping research timelines or substance." Public engagement sat downstream of the technical decisions rather than beside them. Risk communication moved through long internal review cycles, and technical milestones progressed on a calendar that did not change with the political climate. When the political climate shifted, the centre argues, the engagement teams lacked the authority to change the research plan.
What this episode is not
The suspension was not a verdict on the science. The biosafety evidence Target Malaria assembled across thirteen years remains the strongest empirical record of gene-engineering work on the Anopheles genus in African field conditions. The 11 August 2025 release was, by design, neither self-propagating nor irreversible.
Nor was it a rejection of malaria control in Africa. Malaria killed about 579,000 people in the WHO African Region in 2024, and children under five accounted for about 75% of those deaths. Burkina Faso sits inside that burden, and a country facing it does not pause work like this lightly. The IRSS researchers, most of them Burkinabé, did not spend thirteen years on the programme by misreading either the science or the politics.
The episode shows something else: that biosafety approval alone does not secure public acceptance. It secures legal cover. In this case, legal cover did not hold.
What to watch next
The Ugandan team has not publicly walked back its plans. The Target Malaria consortium has said it "remains ready to cooperate" with Burkinabé authorities should the suspension be reviewed. That sentence is the forward path. No realistic open-field release programme in West Africa can proceed without a country that gives its researchers domestic political support.
The harder question is whether donors, Open Philanthropy, the Gates Foundation, the UK BBSRC and the Wellcome Trust, change how they fund engagement relative to laboratory work. The NCSU centre recommends that social science research receive resources comparable to laboratory research, because long-term ethnographic and political work needs sustained investment. Until funders act on that, the next project's path from release to suspension may resemble this one.
For Europe, where the Aedes albopictus gene-engineering question is now discussed for southern France, northern Italy and the Adriatic coast, the lesson transfers. Public engagement designed into a project is cheaper than public engagement added around it. Target Malaria built a regulatory file. The suspension shows it also needed public support.
What we know
Sources cited
- Target Malaria, official suspension statement · https://targetmalaria.org/latest/news/target-malaria-activities-suspended-in-burkina-faso/
- Science (AAAS), report on the suspension of Target Malaria in Burkina Faso · https://www.science.org/content/article/after-humiliating-raid-burkina-faso-halts-gene-drive-project-fight-malaria
- Nature, "Mosquito gene drive cancellation disrupts Africa's malaria research" · https://www.nature.com/articles/d44148-025-00286-z
- NCSU Genetic Engineering and Society Center, "Governing Emerging Technologies: A Lesson from Burkina Faso" (September 2025) · https://ges.research.ncsu.edu/2025/09/blog-governing-emerging-technologies-a-lesson-from-burkina-faso/
- Save Our Seeds, "Burkina Faso halts Target Malaria project" · https://www.saveourseeds.org/news/burkina-faso-halts-target-malaria-project/
- Target Malaria, "Target Malaria proceeded with a small-scale release of genetically modified sterile male mosquitoes in Bana, a village in Burkina Faso" · https://targetmalaria.org/latest/blog/target-malaria-proceeded-with-a-small-scale-release-of-genetically-modified-sterile-male-mosquitoes-in-bana-a-village-in-burkina-faso/
- Target Malaria, "Where we operate" · https://targetmalaria.org/about-us/where-we-operate/
- World Health Organization, Malaria fact sheet · https://www.who.int/news-room/fact-sheets/detail/malaria